<DOC>
	<DOCNO>NCT02762955</DOCNO>
	<brief_summary>CALYPSO clinical study phase 3 study carry establish efficacy , safety pharmacokinetic equivalence BCD-055 ( adalimumab , manufacture JSC BIOCAD , Russia ) Humira® use patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Comparative Clinical Trial Efficacy Safety BCD-057 Humira® Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>CALYPSO study next step clinical evaluation adalimumab biosimilar manufacture joint-stock company ( JSC ) BIOCAD , Russia.The aim study establish BCD-057 equivalent Humira® term efficacy , safety pharmacokinetics use standard regimen patient plaque psoriasis . The study enroll 344 patient moderate severe plaque psoriasis , randomize 2 group ( 1:1 ratio ) : patient first group receive BCD-057 subcutaneously ( SC ) dose 80 mg week 0 , dose 40 mg week 1 , 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 41 , 43 , 45 , 47 , 49 51 ; patient second group receive Humira® regimen .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient write informed consent . Age 18 75 year . Patient moderate severe plaque psoriasis stable course disease 6 month Patient least 1 course phototherapy systemic treatment psoriasis candidate treatment opinion Investigator . BSA affect psoriasis ≥ 10 % , PASI score ≥ 12 , sPGA score ≥ 3 . Patient hemoglobin ≥ 10 g/dl , leucocytes count ≥ 3 000/mcl , thrombocytes count ≥ 100 000/mcl , neutrophil count ≥ 2 000/mcl , aspartate aminotransferase , alanine aminotransferase alkaline phosphatase exceed 2,5 less time upper limit normal range creatinine le 176,8 µmol/l , serologic virologic marker hepatitis B virus hepatitis C virus , negative urine pregnancy test , sign tuberculosis ( negative tuberculosis skin test negative quantiferon test . Patients include positive tuberculin test , Bacteria CalmetteGuerin ( BCG ) vaccination negative Diaskintest negative quantiferon test . Patients include positive tuberculin test , vaccinate BCG also patient positive uncertain quantiferon test/Diaskintest document adequate prophylaxis tuberculosis finish first adalimumab injection AND document absence contact patient active tuberculosis AND sign tuberculosis chest XRay perform 3 month randomization ) Patients able perform procedure plan protocol . Patients ready contraception reliable method start 2 week enter study , 4 week last dose study drug . Subject diagnose erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis , skin condition time screen visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis . Previous receipt adalimumab , history use biological antitumor necrosis factoralpha therapy . Prior use two biologics treatment psoriasis . Previous receipt monoclonal antibody cancel less 12 week screen Patient take corticosteroid 4 week sign informed consent screening , diseasemodifying drug include methotrexate , sulfasalazin cyclosporin 4 week sign informed consent , leflunomide , cyclophosphamide 6 month sign informed consent , phototherapy include selective phototherapy photochemotherapy 4 week sign informed consent , live attenuate vaccine 8 week sign informed consent . Subject discontinue systemic therapy and/or topical therapy treatment psoriasis avoid phototherapy . Subject plan surgical intervention study surgical intervention le 30 day prior study . Subject active infection history infection follow : active infection systemic antiinfectives use within 28 day prior sign informed consent ; serious infection , define require hospitalization intravenous antiinfectives within 8 week prior sign informed consent ; recurrent chronic infection active infection , opinion Investigator , might cause study detrimental subject . Subject known history human immunodeficiency virus severe immunodeficiency . Hepatitis B surface antigen Hepatitis B core antigen Hepatitis C antibody positivity screen . History tuberculosis . Positive result rapid plasma reagintest T.pallidum screening . Active ongoing disease psoriasis might confound evaluation benefit treatment adalimumab increase risk adverse reaction : acute inflammatory disease exacerbation chronic disease otherwise psoriasis ; stable ischemic heart disease IIIIV functional class , unstable angina history myocardial infarction less 1 year signing informed consent ; moderate severe heart failure ( New York Heart Association [ NYHA ] class III/IV ; severe resistant arterial hypertension , atopic bronchial asthma , history angiooedema , moderate severe respiratory insufficiency , chronic obstructive lung disease 34 grade , decompensated diabetes mellitus , systemic autoimmune disease , active neurologic disorder symptom , underlie condition ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal ) opinion investigator significantly immunocompromises patient and/or place patient unacceptable risk receive immunomodulatory therapy . Subject history malignancy within 5 year EXCEPT treat consider cured cutaneous squamous basal cell carcinoma , situ cervical cancer , OR situ breast ductal carcinoma . Subject history hypersensitivity active substance excipients adalimumab BCD057 monoclonal antibody . Female subject pregnant breastfeeding consider become pregnant study . Subject mental illness , include severe depressive disorder / suicidal thought history , , opinion investigator , may create excessive risk patient influence patient 's ability follow protocol . History drug addiction , alcoholism . Simultaneous participation clinical trial , well former participation clinical trial within 3 month study initiation ; previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>adalimumab</keyword>
	<keyword>biosimilar</keyword>
	<keyword>BCD-057</keyword>
	<keyword>psoriasis</keyword>
	<keyword>tumor necrosis factor</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>